Chemical Treatment for Osteoporosis
Case ID:
TEC2013-0086
Web Published:
6/28/2017
Executive Summary
Currently available therapeutics for osteoporosis have the potential to produce severe negative side effects or are required to be administered via injection. Researchers at Michigan State University have developed a new therapeutic that overcomes these challenges.
Description of Technology
This novel MSU technology uses high molecular weight polyethylene glycol (HMW-PEG) to treat osteoporosis. HMW-PEG has been previously shown to enhance GI mucinous and cytoskeletal barriers that prevent pathogenic gut bacteria from interacting with or invading the gut wall at points of weakness leading to systemic inflammation. Inflammation has been linked to bone loss leading to osteoporosis. Here, the inventor has demonstrated that HMW-PEG has positive effects on bone formation in mice. This novel therapeutic is administered orally and is also suitable for animal health.
Key Benefits
- Minimal side effects
- Easy delivery - orally taken
- Promotes bone formation
Applications
- Osteoporosis treatment
- Bone degeneration conditions
Patent Status:
PCT/US2014/028832
Licensing Rights Available
Field specific licensing rights available for use in animal health.
Inventors: Laura McCabe, Rifat Pamukcu
Tech ID: TEC2013-0086
Patent Information:
| App Type |
Country |
Serial No. |
Patent No. |
File Date |
Issued Date |
Expire Date |
For Information, Contact:
Anne Di Sante
Executive Director
Michigan State University
disante@msu.edu
